{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:49:52Z","timestamp":1794646192071,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Routine to Research (R2R) unit, Faculty of Medicine Siriraj Hospital, Mahidol University","award":["(IO) R016535006"],"award-info":[{"award-number":["(IO) R016535006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13684-1","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:14:57Z","timestamp":1739772897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome"],"prefix":"10.1186","volume":"25","author":[{"given":"Concord","family":"Wongkraisri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriengkrai","family":"Chusuwanrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apirom","family":"Laocharoenkeat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Chularojanamontri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akarin","family":"Nimmannit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthinee","family":"Ithimakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"4","key":"13684_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","volume":"1","author":"E Nagore","year":"2000","unstructured":"Nagore E, Insa A, Sanmart\u00edn O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225\u201334.","journal-title":"Am J Clin Dermatol"},{"issue":"19","key":"13684_CR2","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","volume":"28","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28(19):3191\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"13684_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/NCC.0000000000001008","volume":"45","author":"TC Lan","year":"2022","unstructured":"Lan TC, Tsou PH, Tam KW, Huang TW. Effect of urea cream on Hand-Foot syndrome in patients receiving chemotherapy: a Meta-analysis. Cancer Nurs. 2022;45(5):378\u201386.","journal-title":"Cancer Nurs"},{"issue":"22","key":"13684_CR4","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","volume":"33","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, et al. Mapisal Versus Urea cream as Prophylaxis for Capecitabine-Associated Hand-Foot syndrome: a Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol. 2015;33(22):2444\u20139.","journal-title":"J Clin Oncol"},{"issue":"35","key":"13684_CR5","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf SL, Qin R, Menon SP, Rowland KM Jr., Thomas S, Delaune R, et al. Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010;28(35):5182\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"13684_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.14486","volume":"46","author":"S Lian","year":"2021","unstructured":"Lian S, Zhang X, Zhang Y, Zhao Q. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol. 2021;46(4):629\u201335.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"13684_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12282-018-0879-z","volume":"25","author":"T Toyama","year":"2018","unstructured":"Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, et al. A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. Breast Cancer. 2018;25(6):729\u201335.","journal-title":"Breast Cancer"},{"issue":"8","key":"13684_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"Z Ren","year":"2015","unstructured":"Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894\u2013900.","journal-title":"J Clin Oncol"},{"key":"13684_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.09.012","volume":"140","author":"YS Lee","year":"2020","unstructured":"Lee YS, Jung YK, Kim JH, Cho SB, Kim DY, Kim MY, et al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: a multicenter, randomised, double-blind controlled study. Eur J Cancer. 2020;140:19\u201327.","journal-title":"Eur J Cancer"},{"issue":"11","key":"13684_CR10","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","volume":"30","author":"JGP Pandy","year":"2022","unstructured":"Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022;30(11):8655\u201366.","journal-title":"Support Care Cancer"},{"issue":"10","key":"13684_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1177\/1060028015594451","volume":"49","author":"T Yokokawa","year":"2015","unstructured":"Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, et al. Risk factors exacerbating Hand-Foot skin reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy. Ann Pharmacother. 2015;49(10):1120\u20134.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"13684_CR12","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/bjc.2012.434","volume":"107","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107(10):1678\u201383.","journal-title":"Br J Cancer"},{"key":"13684_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","volume":"35","author":"PG Kluetz","year":"2016","unstructured":"Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in Cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes Version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67\u201373.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"13684_CR14","doi-asserted-by":"crossref","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696\u2013704.","DOI":"10.1056\/NEJMoa043116"},{"issue":"24","key":"13684_CR15","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","volume":"28","author":"YK Kang","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13684_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/01.coc.0000217818.07962.67","volume":"29","author":"EH Lin","year":"2006","unstructured":"Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006;29(3):232\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"13684_CR17","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ijc.31269","volume":"142","author":"XZ Huang","year":"2018","unstructured":"Huang XZ, Chen Y, Chen WJ, Zhang X, Wu CC, Wang ZN, et al. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer. 2018;142(12):2567\u201377.","journal-title":"Int J Cancer"},{"issue":"10","key":"13684_CR18","doi-asserted-by":"publisher","first-page":"e15774","DOI":"10.1111\/dth.15774","volume":"35","author":"YS Kao","year":"2022","unstructured":"Kao YS, Lo CH, Tu YK, Hung CH. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: a network meta-analysis of randomized control trials. Dermatol Ther. 2022;35(10):e15774.","journal-title":"Dermatol Ther"},{"issue":"6","key":"13684_CR19","first-page":"1585","volume":"22","author":"LT Macedo","year":"2014","unstructured":"Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585\u201393.","journal-title":"Support Care Cancer"},{"issue":"7","key":"13684_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92(7):1759\u201368.","journal-title":"Cancer"},{"issue":"4","key":"13684_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C, Di\u00e8ras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40(4):536\u201342.","journal-title":"Eur J Cancer"},{"issue":"4","key":"13684_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"13684_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1023\/A:1012281104865","volume":"12","author":"JA Oshaughnessy","year":"2001","unstructured":"Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer. Ann Oncol. 2001;12(9):1247\u201354.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13684-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:59:15Z","timestamp":1739815155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13684"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13684-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Siriraj Hospital, Mahidol University (Date October 15, 2021\/COA No.SI 790\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}